Abstract
Conclusions: We have obtained in-treatment dose distributions and DVHs for each of the different respiratory phases using in-treatment 4D kV CBCT and linac parameters during lung VMAT delivery. Our data showed small variations in dose distributions and DVHs between maximum exhalation and maximum inhalation phases possibly because the tumor size was small and a body frame was used to restrict the patient breathing motion. Dose discrepancies between different phases may be increased for a larger tumor under a free breathing condition. It is further anticipated that deformable registration needs to be implemented to evaluate accumulated dose for an entire treatment delivery.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
